Unilife — Q3 FY2014 Earnings Presentation
13 slides from Unilife's earnings presentation, May 14, 2014
Slide 1: Fiscal Year 2014 3rd Quarter Earnings Call
Exhibit 99.2 rd FiscalYear20143 QuarterEarnings Call May 12,2014
Slide 2: Cautionary Note Regarding Forward-Looking Statements
CautionaryNote RegardingForward-LookingStatements Thispresentationcontainsforward lookingstatementsunderthe safeharbor provisionsof the USsecuritieslaws.Theseforward-lookingstatementsarebased on management’sbeliefsandassumptionsandon informationcurrentlyavailable to our management. Ourmanagementbeli
Slide 3: Opening Comments
Opening Comments $22.6MM in cash receipts from customers during the first nine months of FY 2014, with $10.9MM during Current Quarter $60MM debt financing with OrbiMed Generating cash receipts from ten ongoing customer programs, including several wearable injector programs Clear pathway to profitabi
Slide 4: Participating in Large, Growing Markets
Participating in Large, Growing Markets Market Segment Market Size* Market Trends / Unmet Needs Position of Unilife • Needlestick safety compliance. • Broad, customizable platform for all • $2B market Prefilled Syringes • High-performance biologics prefilled drugs, biologics and vaccines • 13.5% CAG
Slide 5: Unilife is Much Like an Annuity Business Model
Unilife is Much Like an Annuity Business Model Differentiated devices become part of the regulatory drug label Long-term supply contracts that ensure continuity of supply Each supply contract provides recurring annual revenue with intrinsic growth year over year New customers increase revenue and ra
Slide 6: Scaling up for Existing and New Programs
Scaling up for Existing and New Programs Ten ongoing customer programs as of March 31, 2014 Expanding operational infrastructure and cleanrooms Unifill ® platform of prefilled syringes Capacity for existing line largely sold or reserved for customers Additional lines on order for other Unifill produ
Slide 7: OrbiMed Debt Financing
OrbiMed Debt Financing $60MM debt financing with OrbiMed, the world’s largest dedicated healthcare investor $40MM received by Unilife to-date Unilife has the option to receive two extra tranches of $10MM each in December 2014 and June 2015* Interest only payments of approximately $1MM per quarter Ca
Slide 8: Cash Receipts from Customers
Cash Receipts from Customers 8
Slide 9: Net Operating Cash Flow Loss
Net Operating Cash Flow Loss 9
Slide 10: Financial Results for Third Quarter of Fiscal 2014
Financial Results for Third Quarter of Fiscal 2014 Revenue of $1.4MM* Deferred revenue increased by $8.3MM to $18.4MM $39.7MM of total cash and cash equivalents including restricted cash as of March 31, 2014 Three Months Ended Nine Months Ended March 31, March 31, 2014 2013 2014 2013 Revenues $1.4MM
Slide 11: Fiscal Year 2014 Full Year Guidance
Fiscal Year 2014 Full Year Guidance Expected recognized revenue for FY 2014 to be in range of $12MM - $15MM Commercial sales to begin comprising larger share of revenue from FY 2015 onwards 11
Slide 12: Closing Statements
Closing Statements Increasing cash position via cash receipts and OrbiMed deal Increasing base of pharmaceutical and biotech customers Increasing number of customer programs with ten now ongoing and activity underway across all product platforms Increasing revenue with $12 - $15MM target for FY 2014
Slide 13: Questions
Questions